Literature DB >> 24486081

Maple Syrup Urine Disease Complicated with Kyphoscoliosis and Myelopathy.

Jia-Woei Hou1.   

Abstract

Maple syrup urine disease (MSUD) is an autosomal recessive aminoacidopathy secondary to an enzyme defect in the catabolic pathway of the branched-chain amino acids (BCAAs: leucine, isoleucine, and valine). Accumulation of their corresponding keto-acids leads to encephalopathy if not treated in time. A newborn male patient was suspected to have MSUD after tandem mass study when he presented symptoms and signs suggestive neonatal sepsis, anemia, and diarrhea. Food restriction of BCAAs was started; however, acrodermatitis enteropathica-like skin eruptions occurred at age 2 months. The skin rashes resolved after adding BCAAs and adjusting the infant formula. At age 7 months, he suffered from recurrent skin lesions, zinc deficiency, osteoporosis, and kyphosis of the thoracic spine with acute angulation over the T11-T12 level associated with spinal compression and myelopathy. After supplementation of zinc products and pamidronate, skin lesions and osteopenia improved gradually. Direct sequencing of the DBT gene showed a compound heterozygous mutation [4.7 kb deletion and c.650-651insT (L217F or L217fsX223)]. It is unusual that neurodegeneration still developed in this patient despite diet restriction. Additionally, brain and spinal magnetic resonance imaging, bone mineral density study, and monitoring of zinc status are suggested in MSUD patients.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  DBT gene; acrodermatitis enteropathica; maple syrup urine disease; myelopathy; zinc deficiency

Mesh:

Year:  2014        PMID: 24486081     DOI: 10.1016/j.pedneo.2013.10.013

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  1 in total

1.  Acrodermatitis Dysmetabolica--Report of Two Cases.

Authors:  Neerja Gupta; Puneet Jain; Madhulika Kabra; Sheffali Gulati; Gomathy Sethuraman
Journal:  Indian J Pediatr       Date:  2015-02-15       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.